Výsledky vyhledávání - "Rituximab/administration & dosage"

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Autor: Barbara Eichhorst, Carsten U. Niemann, Arnon P. Kater, Moritz Fürstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar da Cunha-Bang, Christof Schneider, Christian B. Poulsen, Thomas Illmer, Björn Schöttker, Thomas Nösslinger, Ann Janssens, Ilse Christiansen, Michael Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jäger, Maria B.L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna-Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens-Martin Wendtner, Karl A. Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek

Publikováno v: Eichhorst, B, Niemann, C U, Kater, A P, Fürstenau, M, von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, da Cunha-Bang, C, Schneider, C, Poulsen, C B, Illmer, T, Schöttker, B, Nösslinger, T, Janssens, A, Christiansen, I, Baumann, M, Frederiksen, H, van der Klift, M, Jäger, U, Leys, M B L, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H, Enggaard, L, Goede, J, Regelink, J C, Widmer, A, Simon, F, De Silva, N, Fink, A-M, Bahlo, J, Fischer, K, Wendtner, C-M, Kreuzer, K A, Ritgen, M, Brüggemann, M, Tausch, E, Levin, M-D, van Oers, M, Geisler, C, Stilgenbauer, S, Hallek, M, German CLL Study Group (GCLLSG), Haemato-Oncology Foundation for Adults in the Netherlands (HOVON), Nordic CLL Study Groups, Swiss Group for Clinical Cancer Research (SAKK), The Israeli CLL Association & Cancer Trials Ireland 2023, ' First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia ', The New England Journal of Medicine, vol. 388, no. 19, pp. 1739-1754 . https://doi.org/10.1056/NEJMoa2213093

BACKGROUNDRandomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.METHODSIn a phase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57065540dd32adf0cc1d031449d13807
https://vbn.aau.dk/da/publications/3cae35e7-c81b-42b3-8598-001ac74af83e

Zobrazit plný text záznamu

Buenas Prácticas en la Administración de Rituximab: Revisión Integradora de la Literatura

Autor: Rodrigues, Carmelita Almeida, Lima, Maria Theresa Camilo de, De Domenico, Edvane Birelo Lopes

Publikováno v: Revista Brasileira de Cancerologia; Vol. 68 No. 3 (2022): July/Aug./Sept.; e-112194
Revista Brasileira de Cancerologia; Vol. 68 Núm. 3 (2022): jul./ago./sept; e-112194
Revista Brasileira de Cancerologia; v. 68 n. 3 (2022): jul./ago./set.; e-112194
Revista Brasileira de Cancerologia
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA

Introduction: Rituximab is a mouse/human chimeric monoclonal antibody, widely used in the therapeutic setting of various diagnoses, due to its different administration, management and adverse effects protocols; its use requires attention by the healt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3056::ee1ed0d585f357fccce123ac1b055ac6
https://rbc.inca.gov.br/index.php/revista/article/view/2194

Zobrazit plný text záznamu

Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy

Publikováno v: American Journal of Hematology
American Journal of Hematology, Wiley, 2021, 96 (8), pp.934-944. ⟨10.1002/ajh.26209⟩
American Journal of Hematology, 2021, 96 (8), pp.934-944. ⟨10.1002/ajh.26209⟩

International audience; Prolonged Covid-19 is an emerging issue for patients with lymphoma or immune deficiency. We aimed to examine prolonged length of in-hospital stay (LOS) due to Covid-19 among patients with lymphoma and assess its determinants a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7c93552a83f08f61d53fc23e10bf133
https://doi.org/10.1002/ajh.26209

Zobrazit plný text záznamu

Avacopan for the Treatment of ANCA-Associated Vasculitis

Autor: Jayne, David R W, Merkel, Peter A, Schall, Thomas J, Bekker, Pirow, ADVOCATE Study Group:, C Au Peh, Chakera, A, Cooper, B, Kurtkoti, J, Langguth, D, Levidiotis, V, Luxton, G, Mount, P, Mudge, D, Noble, E, Phoon, R, Ranganathan, D, Ritchie, A, Ryan, J, Suranyi, M, Rosenkranz, A, Lhotta, K, Kronbichler, A, Demoulin, N, Bovy, C, Hellemans, R, Hougardy, J, Sprangers, B, Wissing, K, Pagnoux, C, Barbour, S, Brachemi, S, Cournoyer, S, Girard, L, Laurin, L, Liang, P, Philibert, D, Walsh, M, Tesar, V, Becvar, R, Horak, P, Rychlik, I, Szpirt, W, Dieperink, H, Gregersen, J, Ivarsen, P, Krarup, E, Lyngsoe, C, Rigothier, C, Augusto, J, Belot, A, Chauveau, D, Cornec, D, Jourde-Chiche, N, Ficheux, M, Karras, A, Klein, A, Maurier, F, Mesbah, R, Moranne, O, Neel, A, Quemeneur, T, Saadoun, D, Terrier, B, Zaoui, P, Schaier, M, Benck, U, Bergner, R, Busch, M, Floege, J, Grundmann, F, Haller, H, Haubitz, M, Hellmich, B, Henes, J, Hohenstein, B, Hugo, C, Iking-Konert, C, Arndt, F, Kubacki, T, Kotter, I, Lamprecht, P, Lindner, T, Halbritter, J, Mehling, H, Schönermarck, U, Venhoff, N, Vielhauer, V, Witzke, O, Szombati, I, Szucs, G, Garibotto, G, Alberici, F, Brunetta, E, Dagna, L, S De Vita, Emmi, G, Gabrielli, A, Manenti, L, Pieruzzi, F, Roccatello, D, Salvarani, C, Dobashi, H, Atsumi, T, Fujimoto, S, Hagino, N, Ihata, A, Kaname, S, Kaneko, Y, Katagiri, A, Katayama, M, Kirino, Y, Kitagawa, K, Komatsuda, A, Kono, H, Kurasawa, T, Matsumura, R, Mimura, T, Morinobu, A, Murakawa, Y, Naniwa, T, Nanki, T, Ogawa, N, Oshima, H, Sada, K, Sugiyama, E, Takeuchi, T, Taki, H, Tamura, N, Tsukamoto, T, Yamagata, K, Yamamura, M, P van Daele, Rutgers, A, Teng, Y, Walker, R, Chua, I, Collins, M, Rabindranath, K, J de Zoysa, Svensson, M, Grevbo, B, Kalstad, S, Little, M, Clarkson, M, Molloy, E, I Agraz Pamplona, Anton, J, V Barrio Lucia, Ciggaran, S, M Cinta Cid, M Diaz Encarnacion, X Fulladosa Oliveras, M Soler, J, H Rusinol, M, Praga, M, L Quintana Porras, Segarra, A, Bruchfeld, A, Segelmark, M, Soveri, I, Thomaidi, E, Westman, K, Neumann, T, Burnier, M, Daikeler, T, Dudler, J, Hauser, T, Seeger, H, Vogt, B, Jayne, D, Burton, J, R Al Jayyousi, Amin, T, Andrews, J, Baines, L, Brogan, P, Dasgupta, B, Doulton, T, Flossmann, O, Griffin, S, Harper, J, Harper, L, Kidder, D, Klocke, R, Lanyon, P, Luqmani, R, Mclaren, J, Makanjuola, D, Mccann, L, Nandagudi, A, Selvan, S, O'Riordan, E, Patel, M, Patel, R, Pusey, C, Rajakariar, R, Robson, J, Robson, M, Salama, A, Smyth, L, Sznajd, J, Taylor, J, Merkel, P, Sreih, A, Belilos, E, Bomback, A, Carlin, J, Y Chang Chen Lin, Derebail, V, Dragoi, S, Dua, A, Forbess, L, Geetha, D, Gipson, P, Gohh, R, T Greenwood, G, Hugenberg, S, Jimenez, R, Kaskas, M, Kermani, T, Kivitz, A, Koening, C, Langford, C, Marder, G, Mohamed, A, Monach, P, Neyra, N, Niemer, G, Niles, J, Obi, R, Owens, C, Parks, D, Podoll, A, Rovin, B, Sam, R, Shergy, W, Silva, A, Specks, U, Spiera, R, Springer, J, Striebich, C, Swarup, A, Thakar, S, Tiliakos, A, Tsai, Y, Waguespack, D, M Chester Wasko

Publikováno v: The New England journal of medicine, 384(7), 599-609. Massachussetts Medical Society
New England Journal of Medicine, 384(7), 599-609. MASSACHUSETTS MEDICAL SOC

BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.METHODS: In this randomized, controlled trial, we assigned patients with ANCA-associated vasculitis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d553edd97f205f3734c7f5a24c48d41
https://pure.eur.nl/en/publications/7b911b71-0492-43f2-9ac8-99b4e663ca69

Zobrazit plný text záznamu

MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial

Publikováno v: The Lancet Haematology, 8(2), e110-e121. Lancet Publishing Group
International Extranodal Lymphoma Study Group (IELSG) 2021, ' MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA) : an international, single-arm, phase 2 trial ', The Lancet. Haematology, vol. 8, no. 2, pp. e110-e121 . https://doi.org/10.1016/S2352-3026(20)30366-5
The Lancet. Haematology
Ferreri, Andrés J M; Doorduijn, Jeanette K; Re, Alessandro; Cabras, Maria Giuseppina; Smith, Jeffery; Ilariucci, Fiorella; Luppi, Mario; Calimeri, Teresa; Cattaneo, Chiara; Khwaja, Jahanzaib; Botto, Barbara; Cellini, Claudia; Nassi, Luca; Linton, Kim; McKay, Pam; Olivieri, Jacopo; Patti, Caterina; Re, Francesca; Fanni, Alessandro; Singh, Vikram; ... (2021). MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. The Lancet. Haematology, 8(2), e110-e121. Elsevier 10.1016/S2352-3026(20)30366-5

Background: Secondary CNS lymphoma is a rare but potentially lethal event in patients with diffuse large B-cell lymphoma. We aimed to assess the activity and safety of an intensive, CNS-directed chemoimmunotherapy consolidated by autologous haematopo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0229c2b8052c92ea24b616224b1242b

Zobrazit plný text záznamu

Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children

Publikováno v: The New England journal of medicine, Vol. 382, no. 23, p. 2207-2219 (2020)
N Engl J Med

BACKGROUND: Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin's lymphoma are limited. METHODS: We conducted an open-label, interna

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::744223cf26167119db29672da134c6f0
https://doi.org/10.1056/nejmoa1915315

Zobrazit plný text záznamu

Efficacy of rituximab in refractory RRMS

Publikováno v: Multiple Sclerosis Journal
Multiple Sclerosis Journal, SAGE Publications, 2018, pp.135245851877274. ⟨10.1177/1352458518772748⟩
Multiple Sclerosis Journal, 2018, 25 (6), pp.828-836. ⟨10.1177/1352458518772748⟩

Objective: To investigate the efficacy of rituximab as rescue therapy in patients with relapsing-remitting multiple sclerosis (RRMS) and persistent disease activity confirmed by magnetic resonance imaging (MRI) despite immunosuppressive disease-modif

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::874788c74cae6029d4019a1e0e3149d7
https://pubmed.ncbi.nlm.nih.gov/29722639

Zobrazit plný text záznamu

Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus:results from the British Isles Lupus Assessment Group Biologics Register

Publikováno v: British Isles Lupus Assessment Group Biologics Register 2018, ' Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus : results from the British Isles Lupus Assessment Group Biologics Register ', Rheumatology, vol. 57, no. 3, pp. 470-479 . https://doi.org/10.1093/rheumatology/kex395, https://doi.org/10.1093/rheumatology/kex395
Rheumatology (Oxford, England)

Objectives: To describe the baseline characteristics of SLE patients requiring biologic therapy in the UK and to explore short term efficacy and infection rates associated with rituximab (RTX) use.\ud \ud \ud \ud Methods: Patients commencing biologic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1b01d8f805cb3078383204209b341ad
https://www.research.manchester.ac.uk/portal/en/publications/shortterm-efficacy-and-safety-of-rituximab-therapy-in-refractory-systemic-lupus-erythematosus(24bf5c63-5b8d-424e-8703-a7101217319b).html

Zobrazit plný text záznamu

A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus

Autor: Madhvi, Menon, Paul A, Blair, David A, Isenberg, Claudia, Mauri

Publikováno v: Menon, M, Blair, P A, Isenberg, D A & Mauri, C 2016, ' A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus ', Immunity, vol. 44, no. 3, pp. 683-697 . https://doi.org/10.1016/j.immuni.2016.02.012
Immunity

Summary Signals controlling the generation of regulatory B (Breg) cells remain ill-defined. Here we report an “auto”-regulatory feedback mechanism between plasmacytoid dendritic cells (pDCs) and Breg cells. In healthy individuals, pDCs drive the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6360c924dbe40ed812fed1bc6c4f32df
https://www.research.manchester.ac.uk/portal/en/publications/a-regulatory-feedback-between-plasmacytoid-dendritic-cells-and-regulatory-b-cells-is-aberrant-in-systemic-lupus-erythematosus(1d3ade0f-c5b6-4cc3-b03e-877898151a19).html

Zobrazit plný text záznamu

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort

Autor: Chatzidionysiou, Katerina, Lie, Elisabeth, Nasonov, Evgeny, Lukina, Galina, Hetland, Merete Lund, Tarp, Ulrik, Ancuta, Ioan, Pavelka, Karel, Nordstrom, Dan C., Gabay, Cem, Canhao, Helene, Tomsic, Matija, van Riel, Piet L. C. M., Gomez-Reino, Juan, Kvien, Tore K., van Vollenhoven, Ronald F., Rheumatic Dis Portuguese Register

Publikováno v: Arthritis research & therapy, 18. BioMed Central
Arthritis Research & Therapy, 18. BioMed Central
Chatzidionysiou, K, Lie, E, Nasonov, E, Lukina, G, Hetland, M L, Tarp, U, Ancuta, I, Pavelka, K, Nordström, D C, Gabay, C, Canhão, H, Tomsic, M, van Riel, P L C M, Gomez-Reino, J, Kvien, T K, van Vollenhoven, R F & Rheumatic Diseases Portuguese Register 2016, ' Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort : data from the CERERRA collaboration ', Arthritis Research & Therapy, vol. 18, pp. 50 . https://doi.org/10.1186/s13075-016-0951-z
Arthritis Research & Therapy
Arthritis Research & Therapy, 18, 1, pp. 50
Arthritis Research and Therapy, Vol. 18 (2016) P. 50
Arthritis Research & Therapy, 18, 50

Contains fulltext : 172430.pdf (Publisher’s version ) (Open Access) BACKGROUND: The approved dose of rituximab (RTX) in rheumatoid arthritis is 1000 mg x 2, but some data have suggested similar clinical efficacy with 500 mg x 2. The purpose of this

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::493da2096632b37039403e10e7b3ea9b
https://doi.org/10.1186/s13075-016-0951-z

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání